Reasons for not entering opioid agonist treatment: A survey among high-risk opioid users in Finland

Author:

Prami Tuire1ORCID,Pölkki Mari1ORCID,Ruotsalainen Jarno1ORCID,Nordbeck Elin Banke2,Meyner Susanna2ORCID,Kaski Ari3

Affiliation:

1. Oriola, Espoo, Finland

2. Camurus AB, Lund, Sweden

3. Kuopio Addiction Medicine Center, Kuopio, Finland

Abstract

Aims: To characterise and understand the untreated high-risk opioid user population in Finland, and to determine the reasons why these people do not enter treatment. Methods: The study setting was a half-year cross-sectional survey in Finland during 2021–2022. An electronic questionnaire with 24 structured questions was concluded in 16 needle exchange units. Participants were opioid-dependent people without opioid agonist treatment (OAT), and they answered the survey voluntarily and anonymously. Results: Of the 167 respondents, 62% were men, 53% were aged ≤34 years, 66% had used opioids for >6 years, and 78% used drugs intravenously (IV) daily. The most used opioid (95%) was buprenorphine. Most respondents used opioids as self-medication for withdrawal symptoms (75%), or to treat psychological symptoms (59%) or pain (43%). Of them, 70% also used other substances for recreational purposes. The most common named reasons to stay outside OAT were as follows: seeking treatment is too difficult (37%); treatment is too binding (36%); and fear of actions from authorities (23%). Conclusions: For opioid-dependent respondents who would be eligible for OAT in Finland, treatment awareness is limited. These high-risk opioid users also think that the treatment would be too binding. In conclusion, there is a need for increase in general information about, accessibility to, acceptance for and individualisation of OAT.

Funder

Camurus AB, Lund, Sweden

Publisher

SAGE Publications

Subject

Health Policy,Health (social science)

Reference25 articles.

1. The current status of opioid maintenance treatment in France: a survey of physicians, patients, and out-of-treatment opioid users

2. A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction

3. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction (2021). European Drug Report – Trends and Developments 2021. Available at https://www.emcdda.europa.eu/system/files/publications/13838/TDAT21001ENN.pdf (Accessed Oct 13, 2022).

4. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction (2022). European Drug Report – Trends and Developments 2022. Available at https://www.emcdda.europa.eu/system/files/publications/14644/TDAT22001ENN.pdf (Accessed Oct 13, 2022).

5. Finlex 386/2011 (2011). Ajokorttilaki [Driving Licence Act]. Available at https://www.finlex.fi/fi/laki/ajantasa/2011/20110386 [In Finnish] (Accessed Jun 06, 2023).

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Snow season: The normalisation of cocaine;Nordic Studies on Alcohol and Drugs;2024-03-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3